
1. j trop med hyg. 2018 jul;99(1):84-86. doi: 10.4269/ajtmh.18-0002. epub 2018
may 17.

comparison two genotyping methods distinguishing recrudescence from
reinfection antimalarial drug efficacy/effectiveness trials.

fulakeza jrm(1), banda rl(2), lipenga tr(2), terlouw dj(3)(2), nkhoma sc(2)(3),
hodel em(3)(2).

author information: 
(1)university malawi, college medicine, blantyre, malawi.
(2)malawi-liverpool-wellcome trust clinical research programme, blantyre, malawi.
(3)liverpool school tropical medicine, liverpool, united kingdom.

genotyping allelic variants plasmodium falciparum merozoite surface
proteins 1 2 (msp-1 msp-2), glutamate-rich protein gold
standard distinguishing reinfections recrudescences antimalarial drug
trials. compared performance recently developed 24-single-nucleotide
polymorphism (snp) barcoding assay msp-1 msp-2 genotyping a
cluster-randomized effectiveness trial artemether-lumefantrine and
dihydroartemisinin-piperaquine malawi. rates recrudescence reinfection 
estimated two methods differ significantly (fisher's exact test; p
= 0.887 p = 0.768, respectively). strong agreement the
two methods predicting treatment outcomes resolving genetic complexity
of malaria infections setting. results support use snp 
assay alternative method correcting antimalarial efficacy/effectiveness
data.

doi: 10.4269/ajtmh.18-0002 
pmcid: pmc6085787
pmid: 29785925  [indexed medline]

